Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

8 evidence topics · 11 sources

Healthy volunteers, single intravenous doses: dose-proportional exposure and terminal half-life
Healthy volunteers, single subcutaneous doses of 50 to 600 mg
Subcutaneous bioavailability, time to peak concentration, and half-life

No evidence found.

CSU, multiple doses: dose-linear exposure, accumulation, and target saturation

“Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Increased clearance and lower volumes of distribution were observed in patients who received lower doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Target saturation was observed with a durable clinical response and tryptase suppression with doses ≥ 1.5 mg/kg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Immunogenicity in the phase 2 and phase 3 CSU trials

No evidence found.